Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years
Condition: Attention Deficit Hyperactivity Disorder Intervention: Drug: Amphetamine Extended Release Suspension [Dyanavel] Sponsor: Tris Pharma, Inc. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials